Blueprint Medicines Corp (NAS:BPMC)
$ 102.71 -0.92 (-0.89%) Market Cap: 6.43 Bil Enterprise Value: 6.17 Bil PE Ratio: 0 PB Ratio: 20.71 GF Score: 74/100

Blueprint Medicines Corp Collaborations with Sixth Street and Royalty Pharma - Corporate Call Transcript

Jun 30, 2022 / 12:30PM GMT
Release Date Price: $50.51 (-3.26%)
Operator

Good morning. My name is Daisy, and I'll be your conference coordinator today. At this time, I would like to welcome everyone to the Blueprint Medicines Conference Call. (Operator Instructions)

I would now like to hand over to Jenna Cohen to begin. Jenna, please go ahead.

Jenna Cohen
Blueprint Medicines Corporation - Senior Director & Head of IR

Thank you, Daisy. Good morning, everyone, and welcome to the call. This morning we issued a press release highlighting Blueprint's $1.25 billion transformative, strategic, and nondilutive financing collaboration with Sixth Street and Royalty Pharma. You can access the press release as well as the slides that we'll be reviewing today by going to the Investors section of our website at www.blueprintmedicines.com.

Joining me on today's call are Kate Haviland, our Chief Executive Officer, who will discuss the importance of this deal for Blueprint Medicines; and Mike Landsittel, our Chief Financial Officer, who will review

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot